Abstract
Objective: To investigate whether systemic therapy with 1-alpha,25-dihydroxyvitamin D3 (vitamin D3 [hereinafter, VD3]) prevents tumor formation in a hamster buccal pouch model of carcinogenesis. Design: Randomized trial in which a known carcinogen, 7,12-dimethylbenz[a]anthracene (DMBA), was applied to the buccal pouch of 40 hamsters. Animals were randomized to receive systemic VD3 or no treatment and killed at 2, 6, and 14 weeks after the initiation of DMBA exposure. Setting: Academic medical center. Subjects: Forty male golden Syrian hamsters, aged 5 to 6 weeks, were used. Interventions: A dose of 0.25 μg/kg of VD3 via intraperitoneal injection was given to 20 animals 3 times per week. Of the remaining 20 control animals, 5 received placebo vehicle injection, and 15 received no further treatment. Main Outcome Measures: Timing, size, and number of tumors that developed in the 2 groups. Results: Only 1 hamster treated with VD3 developed a confirmed neoplasm compared with 7 of the control animals (P<.01). The mean±SD total diameter of gross lesions per animal in the VD3-treated group was 1.2±1.9 mm compared with 6.8±6.6mm in the control group (P=.03). The time to onset of lesion formation was significantly delayed in those animals treated with VD 3, with a mean±SD time to development of 13.4±0.9 weeks, while the control animals developed lesions at 11.2±1.7 weeks (P=.02). Conclusions: Systemic VD3 therapy delays carcinogenesis in the hamster buccal pouch model. Further investigation into the mechanisms through which VD3 inhibits carcinogenesis may lead to development of effective chemopreventive agents to combat head and neck cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1149-1152 |
| Number of pages | 4 |
| Journal | Archives of Otolaryngology - Head and Neck Surgery |
| Volume | 133 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2007 |
Fingerprint
ASJC Scopus subject areas
- Otorhinolaryngology
Cite this
Treatment with 1-alpha,25-dihydroxyvitamin D3 (vitamin D 3) to inhibit carcinogenesis in the hamster buccal pouch model. / Meier, Jeremy D.; Enepekides, Danny J.; Poirier, Brian; Bradley, Christopher A.; Albala, Joanna S.; Farwell, D Gregory.
In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 133, No. 11, 11.2007, p. 1149-1152.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment with 1-alpha,25-dihydroxyvitamin D3 (vitamin D 3) to inhibit carcinogenesis in the hamster buccal pouch model
AU - Meier, Jeremy D.
AU - Enepekides, Danny J.
AU - Poirier, Brian
AU - Bradley, Christopher A.
AU - Albala, Joanna S.
AU - Farwell, D Gregory
PY - 2007/11
Y1 - 2007/11
N2 - Objective: To investigate whether systemic therapy with 1-alpha,25-dihydroxyvitamin D3 (vitamin D3 [hereinafter, VD3]) prevents tumor formation in a hamster buccal pouch model of carcinogenesis. Design: Randomized trial in which a known carcinogen, 7,12-dimethylbenz[a]anthracene (DMBA), was applied to the buccal pouch of 40 hamsters. Animals were randomized to receive systemic VD3 or no treatment and killed at 2, 6, and 14 weeks after the initiation of DMBA exposure. Setting: Academic medical center. Subjects: Forty male golden Syrian hamsters, aged 5 to 6 weeks, were used. Interventions: A dose of 0.25 μg/kg of VD3 via intraperitoneal injection was given to 20 animals 3 times per week. Of the remaining 20 control animals, 5 received placebo vehicle injection, and 15 received no further treatment. Main Outcome Measures: Timing, size, and number of tumors that developed in the 2 groups. Results: Only 1 hamster treated with VD3 developed a confirmed neoplasm compared with 7 of the control animals (P<.01). The mean±SD total diameter of gross lesions per animal in the VD3-treated group was 1.2±1.9 mm compared with 6.8±6.6mm in the control group (P=.03). The time to onset of lesion formation was significantly delayed in those animals treated with VD 3, with a mean±SD time to development of 13.4±0.9 weeks, while the control animals developed lesions at 11.2±1.7 weeks (P=.02). Conclusions: Systemic VD3 therapy delays carcinogenesis in the hamster buccal pouch model. Further investigation into the mechanisms through which VD3 inhibits carcinogenesis may lead to development of effective chemopreventive agents to combat head and neck cancer.
AB - Objective: To investigate whether systemic therapy with 1-alpha,25-dihydroxyvitamin D3 (vitamin D3 [hereinafter, VD3]) prevents tumor formation in a hamster buccal pouch model of carcinogenesis. Design: Randomized trial in which a known carcinogen, 7,12-dimethylbenz[a]anthracene (DMBA), was applied to the buccal pouch of 40 hamsters. Animals were randomized to receive systemic VD3 or no treatment and killed at 2, 6, and 14 weeks after the initiation of DMBA exposure. Setting: Academic medical center. Subjects: Forty male golden Syrian hamsters, aged 5 to 6 weeks, were used. Interventions: A dose of 0.25 μg/kg of VD3 via intraperitoneal injection was given to 20 animals 3 times per week. Of the remaining 20 control animals, 5 received placebo vehicle injection, and 15 received no further treatment. Main Outcome Measures: Timing, size, and number of tumors that developed in the 2 groups. Results: Only 1 hamster treated with VD3 developed a confirmed neoplasm compared with 7 of the control animals (P<.01). The mean±SD total diameter of gross lesions per animal in the VD3-treated group was 1.2±1.9 mm compared with 6.8±6.6mm in the control group (P=.03). The time to onset of lesion formation was significantly delayed in those animals treated with VD 3, with a mean±SD time to development of 13.4±0.9 weeks, while the control animals developed lesions at 11.2±1.7 weeks (P=.02). Conclusions: Systemic VD3 therapy delays carcinogenesis in the hamster buccal pouch model. Further investigation into the mechanisms through which VD3 inhibits carcinogenesis may lead to development of effective chemopreventive agents to combat head and neck cancer.
UR - http://www.scopus.com/inward/record.url?scp=36349009705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36349009705&partnerID=8YFLogxK
U2 - 10.1001/archotol.133.11.1149
DO - 10.1001/archotol.133.11.1149
M3 - Article
C2 - 18025321
AN - SCOPUS:36349009705
VL - 133
SP - 1149
EP - 1152
JO - JAMA Otolaryngology - Head and Neck Surgery
JF - JAMA Otolaryngology - Head and Neck Surgery
SN - 2168-6181
IS - 11
ER -